CClinicalTrials.gg
CompletedNCT00505544Updated Jul 13, 2022

Measuring Sleep Disturbance Among Cancer Patients

An observational study in Advanced Cancer, sponsored by M.D. Anderson Cancer Center. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-13.

Sponsored by M.D. Anderson Cancer Center · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
459
Ages
18 Years and older
Sex
All
01

Study summary

Objectives:

Primary Objectives:

  1. To establish concurrent criterion-related validity of the Brief Sleep Disturbance Scale (BSDS) by correlating the scale with the Pittsburgh Sleep Quality Index.
  2. To evaluate the construct validity of the BSDS through exploratory factor analysis.
  3. To examine possible predictors of sleep disturbance.
  4. To evaluate the reliability of the BSDS using Cronbach's coefficient alpha and test-retest reliability.
  5. To evaluate the sensitivity of the BSDS by administering it to the same group of patients (n = 60) prior to treatment with a regimen associated with sleep disturbance, during 4 weeks of treatment, and upon completion of treatment.
  6. To evaluate the psychometric properties of the BSDS in a sample of community dwelling adults.

Secondary Objective:

  1. To obtain pilot data from a small sample of patients who will wear an actigraph for one week.
Read the detailed description

Patients Who Complete the Surveys on Multiple Time Points:

This study will teach researchers about changes in your sleep patterns that may happen during your cancer treatment. The participants will be recruited from the Melanoma Clinic.

If you agree to take part in this study, during your cancer treatment, you will be asked to complete three written questionnaires that ask about your sleep, symptoms, and mood. These questionnaires will take about 20 minutes to complete. You will be asked to complete the questionnaires before, during and after your cancer treatment during 11 of your clinic visits.

You will also be asked to fill out a sleep diary at home, in which you will be asked to record what time you go to bed, whether you get up during the night, and what time you wake up. You will be asked to fill out the diary every day, for one week. You will be asked to return it during a clinic visit or by mail, with a stamped envelope that will be provided.

During the study, the research staff will collect information from your medical chart about your cancer, cancer treatment, and laboratory tests.

This is an investigational study. Up to 570 participants will take part in this multicenter study. Up to 380 will be enrolled at MD Anderson.

Patients Who Wear Actigraphs:

This study will help researchers to understand how cancer and cancer treatments affect sleep patterns. The participants will be recruited from the M. D. Anderson outpatient clinics, including Breast, Neuro-oncology, Blood and Marrow Transplantation, Genitourinary Oncology, Gastrointestinal Oncology Gynecologic Oncology, Head and Heck, Thoracic Oncology, Leukemia, Lymphoma, Melanoma, Sarcoma, Internal Medicine, and the Ambulatory Treatment Center.

If you agree to take part in this study, you will be asked to complete eight written questionnaires that have questions about your sleep, symptoms, and mood. These questionnaires will take about 20 minutes to complete. You will be asked to fill out the questionnaires before wearing the actigraph and after one week of wearing the actigraph.

During the study, the research staff will collect information from your medical chart about the cancer, cancer treatment, and laboratory tests.

You will be asked to wear an actigraph on your wrist for one week. An actigraph is a small motion detector that is about the size and shape of a wristwatch. The actigraph will collect and store information on your activity levels and your sleep patterns. You will be asked to return the actigraph at the end of the week.

You will be asked to fill out a sleep diary at home, in which you will be asked to record what time you go to bed, whether you get up during the night, and what time you wake up. You will only be asked to do this during the week you wear the actigraph.

At the end of the "actigraph" week, you will be asked to complete a brief sleep questionnaire, which will take about 5 minutes to complete.

This is an investigational study. About 20 patients will take part in this study. All will be enrolled at MD Anderson.

02

Conditions studied

  • Advanced Cancer

Keywords

  • Advanced Cancer
  • Questionnaire
  • Survey
  • Sleep Disturbance
  • Sleep Quality
03

In context

Dyssomnias

324 studies on the registry are indexed under Dyssomnias; 51 are open to participants now.

This study's enrollment of 459 is above the median of 126 across 63 observational studies indexed under Dyssomnias.

Browse Dyssomnias studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 2,999 studies on the registry; 581 are open to participants now.

Of its 599 completed or terminated interventional studies of FDA-regulated products, 402 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Study participants with a pathological diagnosis of cancer and community dwelling adults who attend a meeting of a designated service organization.

Inclusion criteria

  1. Outpatient or inpatient receiving evaluation, treatment, or follow-up care at MDACC or a collaborating site.
  2. Has a pathological diagnosis of cancer.
  3. 18 years of age or older.
  4. Able to understand English.
  5. Gives informed consent to participate.
  6. Community sample eligibility: Community dwelling adult who attends a meeting of a designated service organization.
  7. Community sample eligibility: 18 years of age or older
  8. Community sample eligibility: Gives Informed Consent to participate.
  9. Community sample eligibility: Able to understand English.

Exclusion criteria

Exclusion Criteria:

  1. Cannot understand the intent of the study.
  2. Patient feels too ill to complete the surveys.
  3. Refuses to participate.
  4. Community sample exclusion criterion: Unable to complete the surveys.
  5. Community sample exclusion criterion: Refuses to participate.
  6. Community sample exclusion criterion: Cancer diagnosis (past or present).
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
459 participants (actual)

Groups and cohorts

  • Questionnaire

    Questionnaires that ask about your sleep, symptoms, and mood.

    Behavioral: Questionnaire

  • Questionnaire + Actigraphs

    Questionnaires that ask about your sleep, symptoms, and mood. Wear actigraph to collect information on activity levels and sleep patterns for one week.

    Behavioral: Questionnaire · Device: Actigraph

Interventions

  • BehavioralQuestionnaire

    Questionnaires that ask about your sleep, symptoms, and mood.

    Also known as: Survey

  • DeviceActigraph

    Wear actigraph to collect information on activity levels and sleep patterns for one week.

06

What researchers measure

Primary outcomes

  1. Sensitivity of Brief Sleep Disturbance Scale (BSDS)

    Time frame: Administering to same group prior to treatment with a regimen associated with sleep disturbance, during 4 weeks of treatment, and upon completion of treatment.

07

Study locations

2 sites
  • Lyndon Baines Johnson General Hospital
    Houston, Texas 77030, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00505544
Lead sponsor
M.D. Anderson Cancer Center
Responsible party
Sponsor
First posted
Jul 23, 2007
Start date
Aug 2005
Primary completion
Jul 11, 2022
Completion
Jul 11, 2022
Last update
Jul 13, 2022

Study contacts

Xin S. Wang, MD,MPH
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion